CRO Canadian Arrow Mines Ltd. (delisted)

ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), ("ProMetic" or the
"Corporation") announced today that its lead drug candidate PBI-4050, is on
track to enter the clinical trial program starting in September 2013. During the
first half of 2013, the Corporation has systematically executed on all key
activities required to enable the initiation of the clinical trials.


The manufacturing process for its orally active anti-fibrotic lead drug
candidate has been successfully scaled up in an FDA and EMA approved facility.
The required GMP material has been delivered to advance the toxicology program
necessary to enable the commencement of the clinical trials. Throughout the
preclinical program, PBI-4050 has demonstrated efficacy with a remarkable safety
profile. This is expected to be further confirmed in the on-going toxicology
studies being performed by a certified contract research organisation ("CRO").


"The recently presented data on PBI-4050 confirms its potential as a novel
therapy to inhibit inflammation and fibrosis which underlies most progressive
chronic renal diseases" stated Dr Raymond Hakim, MD, PhD, a kidney specialist
who until recently was the Chief Medical Officer of one of the largest provider
of renal services in the US and a new member of ProMetic's Board of Directors.
"Diabetes further accelerate the loss of kidney function in patients with CKD,
and the extensive PBI-4050 preclinical data generated suggest that this patient
population would greatly benefit from this therapeutic approach" added Dr Hakim.



In a well-recognized animal model designed to study the long term effect of
diabetes on organs, PBI-4050 reduced kidney hyperfiltration, proteinuria, and
the expression of inflammatory/fibrotic markers in kidney. These results and new
data that further confirms PBI-4050's ability to reduce fibrosis in kidney were
recently presented at the European Renal Association in Istanbul
(http://www.prometic.com/en/therapeutics/scientific-library.php) and at the
world congress in nephrology in Hong Kong
(http://www.prometic.com/en/therapeutics/scientific-library.php). New results
demonstrating the efficacy of PBI-4050 in a challenging pulmonary fibrosis model
will be presented at the forthcoming European Respiratory Society 2013 Meeting
to be held in Barcelona in September.


"Following the initial phase clinical program to confirm safety in humans to be
performed in Q4 this year, we expect to start enrolling patients in early 2014
to demonstrate efficacy" commented Dr John Moran, also a member of ProMetic's
Board of Directors "Patients affected by CKD cost Medicare nearly 75 billion
dollars a year. Needless to say an effective therapy would greatly benefit
patients and reduce the ever-growing costs to the healthcare system" added Dr
Moran. 


"While renal indications may represent the highest value on a long term basis,
the development strategy pursued may also target other fibrotic indications as
point of initial commercial entry" mentioned Pierre Laurin, CEO of ProMetic, who
added "Pulmonary fibrosis for instance, is a good example of an interesting
target indication for which PBI-4050 has demonstrated superior efficacy compared
to the only other commercially available therapy".


More on PBI-4050 

PBI-4050 is one of ProMetic orally active lead drug candidates with efficacy and
high safety profiles confirmed in several in vivo experiments targeting
fibrosis. Fibrosis is a very complex process by which inflammation leads to the
deposit of fibrous material to repair the damaged area and whereby vital organs
gradually lose their functionality as normal and functional tissue is replaced
by fibrotic scarring tissue. The proof of concept data generated to date
confirms our lead drug candidates' anti-fibrotic activity in several key organs
including the kidneys, the heart, the lungs and the liver. Twenty six million
patients in the U.S. alone are diagnosed with chronic kidney diseases ("CKD").
Patients with severe CKD stages (3 and 4) suffer from a gradual and accelerated
loss of their renal function (end stage renal disease or ESRD) leading to the
need for hemodialysis. Cardiovascular complications for ESRD patients on
hemodialysis are a common cause of death. 


The positive effects of PBI-4050 observed in several different animal models
designed to reproduce chronic kidney diseases can be summarized as follows:


Increase in GFR (improvement of the renal function)

Decrease in Proteinuria (reduction of protein found in urine)

Decrease in Serum creatinine (reduction of creatinine in blood)

Decrease in Serum urea (reduction of urea in blood)

Decrease in Histological lesions (reduction of fibrosis & lesions, leading to a
more functional and normal renal tissue)


Decrease of collagen deposition in the tissue

Decrease in several biomarkers confirming the reduction of inflammation and fibrosis

About ProMetic Life Sciences Inc. 

ProMetic Life Sciences Inc. (www.prometic.com) is a long established
biopharmaceutical company with globally recognized expertise in bioseparations,
plasma-derived therapeutics and small-molecule drug development. ProMetic offers
its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base
of industry leaders and uses its own affinity technology that provides for
highly efficient extraction and purification of therapeutic proteins from human
plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic
is also active in developing its own novel small-molecule therapeutic products
targeting unmet medical needs in the field of fibrosis, cancer and autoimmune
diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D
facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK
and business development activities in the U.S., Europe and Asia.


Forward Looking Statements

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 26 of ProMetic's Annual Information Form for the year ended
December 31, 2012, under the heading "Risk and Uncertainties related to
ProMetic's business". As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any
forward-looking statement even if new information becomes available, as a result
of future events or for any other reason, unless required by applicable
securities laws and regulations. All amounts are in Canadian dollars unless
indicated otherwise. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
p.laurin@prometic.com
+1.450.781.0115


Frederic Dumais
Director, Communications and Investor relations
ProMetic Life Sciences Inc.
f.dumais@prometic.com
+1.450.781.0115

Canadian Arrow Mines Limited (TSXV:CRO)
Historical Stock Chart
From May 2024 to Jun 2024

Canadian Arrow Mines Limited (TSXV:CRO)
Historical Stock Chart
From Jun 2023 to Jun 2024